| dbo:abstract |
Sodium oligomannate (development code GV-971) is a mixture of oligosaccharides isolated from the marine algae Ecklonia kurome that is used in China as a treatment for Alzheimer's disease (AD). It was conditionally approved in China by the National Medical Products Administration in 2019 for mild to moderate AD to improve cognitive function. However, the clinical data supporting its potential benefits have been received skeptically elsewhere and are considered insufficient for approval in other countries. Therefore, it is still undergoing Phase III clinical trials necessary for regulatory approval in the United States and Europe. The mechanism by which sodium oligomannate may function is unclear and several possibilities have been proposed, including amyloid beta disaggregation, mediation of inflammatory responses to amyloid plaques, protein binding inside neurons, and alteration of intestinal bacteria. (en) “九期一”（GV-971），学名甘露特钠（英語：sodium oligomannate），是一款用于治疗轻度至中度阿尔茨海默症（俗称老年痴呆症）的药品，据称是中国第一款治疗阿尔茨海默症的原创新药。但它亦引起了不少质疑，包括研发单位上海绿谷制药曾虚假宣传、贩卖假药、研发者耿美玉疑似论文造假。 GV-971提取自，是一种寡糖。其“作用机理”至今不明，其发明者提出了分解Aβ蛋白块、消炎、进入神经细胞和各种蛋白质结合、影响肠道菌群等截然不同的解释。此药的临床试验全都没有允许受试者同时使用其他抗阿尔兹海默药物。 (zh) |
| dbo:casNumber |
2300168-65-2 |
| dbo:wikiPageID |
68047828 (xsd:integer) |
| dbo:wikiPageLength |
6604 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1095737931 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:National_Medical_Products_Administration dbr:Amyloid_beta dbr:Amyloid_plaques dbr:Oligosaccharide dbr:Phase_III_clinical_trials dbr:Alzheimer's_disease dbc:Polysaccharides dbc:Treatment_of_Alzheimer's_disease dbr:Ecklonia_kurome dbr:Mechanism_of_action |
| dbp:casNumber |
2300168 (xsd:integer) |
| dbp:legalStatus |
Conditional approval in China; investigational elsewhere (en) |
| dbp:synonyms |
Sodium oligo-mannurarate; GV-971; GV971 (en) |
| dbp:wikiPageUsesTemplate |
dbt:Clear dbt:Infobox_drug dbt:Nervous-system-drug-stub dbt:Reflist dbt:Short_description |
| dcterms:subject |
dbc:Polysaccharides dbc:Treatment_of_Alzheimer's_disease |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
“九期一”（GV-971），学名甘露特钠（英語：sodium oligomannate），是一款用于治疗轻度至中度阿尔茨海默症（俗称老年痴呆症）的药品，据称是中国第一款治疗阿尔茨海默症的原创新药。但它亦引起了不少质疑，包括研发单位上海绿谷制药曾虚假宣传、贩卖假药、研发者耿美玉疑似论文造假。 GV-971提取自，是一种寡糖。其“作用机理”至今不明，其发明者提出了分解Aβ蛋白块、消炎、进入神经细胞和各种蛋白质结合、影响肠道菌群等截然不同的解释。此药的临床试验全都没有允许受试者同时使用其他抗阿尔兹海默药物。 (zh) Sodium oligomannate (development code GV-971) is a mixture of oligosaccharides isolated from the marine algae Ecklonia kurome that is used in China as a treatment for Alzheimer's disease (AD). It was conditionally approved in China by the National Medical Products Administration in 2019 for mild to moderate AD to improve cognitive function. However, the clinical data supporting its potential benefits have been received skeptically elsewhere and are considered insufficient for approval in other countries. Therefore, it is still undergoing Phase III clinical trials necessary for regulatory approval in the United States and Europe. (en) |
| rdfs:label |
Sodium oligomannate (en) 九期一 (zh) |
| owl:sameAs |
wikidata:Sodium oligomannate dbpedia-zh:Sodium oligomannate https://global.dbpedia.org/id/C86mz |
| prov:wasDerivedFrom |
wikipedia-en:Sodium_oligomannate?oldid=1095737931&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Sodium_oligomannate |
| is dbo:wikiPageRedirects of |
dbr:GV-971 |
| is dbo:wikiPageWikiLink of |
dbr:GV-971 |
| is foaf:primaryTopic of |
wikipedia-en:Sodium_oligomannate |